Francesco De Rubertis
Partner @ Index Ventures
Geneva, Switzerland
Francesco De Rubertis is a Series A investor at Index Ventures in Geneva focused on Biotechnology and Pharmaceutical. Francesco De Rubertis is based out of Geneva, Geneve and is the Co Founder & Partner of Medicxi. Francesco previously worked at Index Ventures as a partner. Francesco De Rubertis attended the University of Geneva.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Francesco De Rubertis invests in
Stages Francesco De Rubertis invests in
Countries Francesco De Rubertis invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.2M–$100M
- Series A
- $11M–$140M
- Series B
- $13M–$132M
Investment Focus
Industry
- Biotechnology 9 (43%)
- Pharmaceutical 5 (24%)
- Health Care 4 (19%)
- Medical 3 (14%)
- Therapeutics 3 (14%)
Stage
- Series A 6 (29%)
- Series B 5 (24%)
- Seed 4 (19%)
- Series C 2 (10%)
- Pre-Seed 1 (5%)
Country
- United States 5 (24%)
- China 1 (5%)
- Spain 1 (5%)
- Ireland 1 (5%)
- Switzerland 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $108M / Series B / Dec 09, 2025 | ||
| Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | $140M / Series A / Dec 19, 2024 | ||
| Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | Seed / Oct 28, 2024 | ||
| D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $62M / Series A / Apr 08, 2024 | ||
| Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi. | $100M / Seed / Feb 12, 2024 | ||
Aldena Therapeutics
|
Aldena Therapeutics is a private biotech startup that invented siRNA-based treatments for dermatological conditions. | $30M / Series A / Mar 16, 2023 | |
| Velada is an app that helps users find the ideal restaurant for any occasion by utilizing data to provide personalized recommendations. Tjey also have a proprietary algorithm that uses data from its users' preferences and app behavior to make personalized recommendations, making Velada the first smart restaurant guide. However, without an appor resource that provides a dedicated local guide, travelers frequently find themselves in tourist traps when it comes to their culinary experience. | $1.2M / Seed / Oct 05, 2022 | ||
| Velada is an app that helps users find the ideal restaurant for any occasion by utilizing data to provide personalized recommendations. Tjey also have a proprietary algorithm that uses data from its users' preferences and app behavior to make personalized recommendations, making Velada the first smart restaurant guide. However, without an appor resource that provides a dedicated local guide, travelers frequently find themselves in tourist traps when it comes to their culinary experience. | $1.1M / Pre-Seed / Oct 05, 2022 | ||
| Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity. | $132M / Series B / Sep 22, 2022 | ||
| Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity. | $35M / Series A / Jul 20, 2021 | ||
| See all 21 investments → | |||
Co-Investors
About Index Ventures
Index Ventures is a venture capital company that provides investment capital and strategic support to early-stage and growth-stage technology enterprises across sectors such as software, fintech, healthcare, and consumer services. It engages with entrepreneurial teams to assess business models, support scaling efforts, and provide guidance through successive development phases. The company’s services include sourcing investment opportunities, conducting due diligence, structuring financing deals, and offering ongoing advisory interactions with portfolio founders. Index Ventures also maintains a network of industry relationships and resources aimed at facilitating connections between founders, investors, and market opportunities. Its focus spans from initial seed rounds through later financing stages to help portfolio companies pursue expansion and market entry efforts.
Index Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Georgia Stevenson
Partner
|
|||
Gerald Rimer
Team Member
|
|||
Hannah Seal
Principal/Partner
|
|||
Jan Hammer
Investor & Partner
|
|||
Julia Andre
Principal/Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Francesco De Rubertis invest in?
Francesco De Rubertis invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Francesco De Rubertis invest in?
Francesco De Rubertis typically joins rounds of $1.2M–$100M at Seed, $11M–$140M at Series A and $13M–$132M at Series B. These are whole funding-round sizes, not Francesco De Rubertis's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Francesco De Rubertis took part in.
How do I contact Francesco De Rubertis?
Public channels for Francesco De Rubertis include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Francesco De Rubertis last invest?
The most recent investment recorded for Francesco De Rubertis closed in Dec 2025. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
